These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 26031842)

  • 21. Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
    Gholizadeh S; Dolman EM; Wieriks R; Sparidans RW; Hennink WE; Kok RJ
    Pharm Res; 2018 Mar; 35(4):85. PubMed ID: 29516187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.
    Pastorino F; Brignole C; Di Paolo D; Perri P; Curnis F; Corti A; Ponzoni M
    Small; 2019 Mar; 15(10):e1804591. PubMed ID: 30706636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
    Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
    Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
    J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of liposomal curcumin in a human pancreatic tumor xenograft model: inhibition of tumor growth and angiogenesis.
    Ranjan AP; Mukerjee A; Helson L; Gupta R; Vishwanatha JK
    Anticancer Res; 2013 Sep; 33(9):3603-9. PubMed ID: 24023285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
    Shen J; Song G; An M; Li X; Wu N; Ruan K; Hu J; Hu R
    Biomaterials; 2014 Jan; 35(1):316-26. PubMed ID: 24125776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a two-in-one liposomal system (TWOLips) for tumor-targeted combination therapy.
    Su T; Long Y; Deng C; Feng L; Zhang X; Chen Z; Li C
    Int J Pharm; 2014 Dec; 476(1-2):241-52. PubMed ID: 25300591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation.
    Sahoo RK; Gothwal A; Rani S; Nakhate KT; Ajazuddin ; Gupta U
    Int J Pharm; 2020 Jun; 584():119389. PubMed ID: 32380027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.
    Yuan S; Li Q; He C; Bing M; Zhang X; Xu H; Wang Z; Zhao M; Zhang Y; Chai Y; Li B; Zhuang W
    Blood Adv; 2024 Sep; 8(18):4886-4899. PubMed ID: 38875465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
    Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Kiziltepe T; Bilgicer B
    J Med Chem; 2014 Jun; 57(12):5282-92. PubMed ID: 24897555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
    Gu Z; Chang M; Fan Y; Shi Y; Lin G
    Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
    Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligand-targeted liposomal therapies of neuroblastoma.
    Pastorino F; Marimpietri D; Brignole C; Di Paolo D; Pagnan G; Daga A; Piccardi F; Cilli M; Allen TM; Ponzoni M
    Curr Med Chem; 2007; 14(29):3070-8. PubMed ID: 18220743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.